YOLFTbeta
Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics Corp.

TTI · V · Healthcare / Biotechnology

0.65CAD+0.01 (+1.56%)

Price History

Full chart

Market Stats

Previous Close0.64
Open0.65
Day Range0.60 – 0.65
52-Week Range0.44 – 0.81
Volume14.50K
Market Cap34.29M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.12
Dividend Yield0.00%
Beta0.61
50-Day Avg0.525
200-Day Avg0.552

About

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered in Toronto, Canada.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Patrice P. Rioux M.D., Ph.D.
  • Employees0
  • Headquarters4 King Street West, Toronto, ON, Canada, M5H 1B6, Canada
  • Websitehttps://thiogenesis.com

Leadership

  • Dr. Patrice P. Rioux M.D., Ph.D.Co-Founder, CEO & Director · b. 1951
  • Mr. Brook G. Riggins C.F.A.CFO, Secretary & Director · b. 1966
  • Ms. Mary Jo BaggerConsultant for Clinical Operations

Financials

Income Statement

Currency: CAD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue0000000
Operating Income-73.42K-92.65K-224.68K-1.97M-5.21M-3.58M-7.40M
EBITDA-73.34K--224.43K-3.92M-5.21M-3.58M-7.40M
Net Income-73.34K-92.68K-224.46K-3.92M-5.06M-3.15M-7.43M
R&D116.44K499.70K1.37M1.08M4.16M2.22M5.77M
Interest Expense025264.12K0--

Balance Sheet

Currency: CAD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets292.49K146.43K3.43M6.29M7.24M3.98M1.81M
Total Liabilities12.22K63.08K3.49M307.15K1.71M557.88K1.24M
Total Equity280.27K83.35K-61.07K5.98M5.53M3.43M574.38K
Cash183.51K19.22K62.55K6.20M7.08M3.85M1.62M
Net Debt-300.78K399.31K----

Cash Flow

Currency: CAD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-199.58K-35.88K-67.08K-2.09M-3.25M-3.92M-6.03M
Financing Cash Flow352.69K1103.33M8.13M4.12M723.40K3.81M
Capital Expenditure0000000
Free Cash Flow-199.58K-35.88K-67.08K-2.09M-3.25M-3.92M-6.03M
FCF to OCF100.00%100.00%100.00%100.00%100.00%100.00%100.00%

Earnings

Report DateNov 26, 2026
EPS Estimate-
EPS Actual-
Surprise-
TimingAfter-hours

Key Statistics & Ratios

Market Cap34.29M
Enterprise Value31.91M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book5.83
EPS-0.12
Book Value0.096
Revenue (TTM)0
Gross Profit (TTM)0
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-181.53%
Return on Assets-87.22%
Shares Outstanding69.98M
Shares Float55.42M
Beta0.61
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%